List of Excipients in Branded Drug MOLINDONE HYDROCHLORIDE

Generic Drugs Containing MOLINDONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
EPIC PHARMA LLC	molindone hydrochloride	42806-336	ALGINIC ACID
EPIC PHARMA LLC	molindone hydrochloride	42806-336	CALCIUM SULFATE
EPIC PHARMA LLC	molindone hydrochloride	42806-336	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in MOLINDONE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ALGINIC ACID
1	CALCIUM SULFATE
1	CELLULOSE, MICROCRYSTALLINE

Molindone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Molindone hydrochloride is an older, orally administered typical antipsychotic with limited current commercial competition and no meaningful patent barrier apparent in public FDA records. The strongest opportunities are low-cost generic manufacture, supply continuity, dose-form simplification, and differentiated oral products using excipients that improve manufacturability, stability, swallowability, or dose flexibility. The commercial ceiling is constrained by small market demand, competition from newer antipsychotics, and the absence of a large branded franchise.

What is molindone hydrochloride and how is it marketed?

Molindone hydrochloride is the hydrochloride salt of molindone, a dopamine D2-antagonist antipsychotic historically marketed in the United States under the brand name Moban. The reference product was approved by the FDA in the 1970s and was later discontinued. Generic molindone hydrochloride tablets have been marketed in multiple strengths.

Attribute	Description
Active ingredient	Molindone hydrochloride
Therapeutic class	Typical antipsychotic
Primary dosage form	Immediate-release oral tablet
Historical brand	Moban
Original U.S. approval	1970s
Typical strengths	5 mg, 10 mg, 25 mg, 50 mg and 100 mg
FDA pathway for a standard generic	Abbreviated New Drug Application, or ANDA
Current commercial position	Niche, generic-oriented product with limited market visibility
Biosimilar exposure	None; molindone hydrochloride is a small molecule
Main development barrier	Small addressable market rather than active composition-of-matter exclusivity

Molindone is not a biologic, so biosimilar competition does not apply. Competition would arise through generic tablets, reformulated oral products, hospital supply contracts, and potentially 505(b)(2) products with differentiated delivery or administration characteristics.

What patents protect molindone hydrochloride?

Publicly available FDA Orange Book information does not indicate a significant current patent estate protecting molindone hydrochloride tablets. The original product and its early development-era intellectual property are old, and any conventional composition-of-matter protection would have expired.

Patent position

Patent category	Commercial relevance
Original compound patent	Expected to be expired
Original tablet formulation patent	Expected to be expired or commercially irrelevant
Current Orange Book-listed patent estate	No significant estate identified for standard molindone hydrochloride tablets
Method-of-use patents	No material current barrier identified for ordinary antipsychotic use
Manufacturing patents	Potentially available for new processes, but unlikely to block conventional generic production
Excipient patents	Available only for genuinely novel formulation systems or delivery technologies
Patent litigation exposure	Low for a conventional immediate-release generic

The absence of a meaningful patent barrier does not guarantee commercial success. Molindone hydrochloride remains a low-volume product, and manufacturing economics, FDA compliance, and channel access are more important than patent clearance.

When does molindone hydrochloride lose exclusivity?

Molindone hydrochloride lost practical market exclusivity many years ago. The original brand product has no meaningful remaining exclusivity period comparable to newer antipsychotics.

FDA exclusivity considerations

For a conventional ANDA:

• No new chemical entity exclusivity remains.
• No current three-year exclusivity is expected for a routine generic tablet.
• No orphan-drug exclusivity is apparent for the standard indication.
• Pediatric exclusivity is not a current commercial factor.
• Patent certification would depend on the patents listed for the relevant reference product, if any remain listed.

The principal regulatory task is therefore demonstrating pharmaceutical equivalence and bioequivalence to the applicable reference standard, not overcoming a current branded patent wall.

What excipients are used in molindone hydrochloride tablets?

Public labeling for molindone hydrochloride products has identified conventional tablet excipients, although the exact composition can differ by manufacturer and strength. Reported inactive ingredients for generic products have included common diluents, binders, disintegrants, lubricants, glidants, and processing aids.

Potential excipient classes include:

Excipient function	Examples used or commercially plausible
Diluent	Lactose monohydrate, microcrystalline cellulose, pregelatinized starch
Binder	Povidone, starch, hydroxypropyl cellulose
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubricant	Magnesium stearate, sodium stearyl fumarate
Glidant	Colloidal silicon dioxide
Surfactant or wetting agent	Sodium lauryl sulfate
Coating system	Hypromellose, polyethylene glycol, titanium dioxide, approved colorants
Taste-masking system	Polymer film coating, ion-exchange resin, lipid coating

The product’s old-market status favors excipient systems that are inexpensive, globally available, compendial, and familiar to FDA reviewers. A complex excipient platform would need to produce a clear benefit, such as improved stability, easier swallowing, or a clinically meaningful administration advantage.

How should a manufacturer design the excipient system?

The preferred base strategy is a robust immediate-release tablet with a conventional composition and a manufacturing process that supports low-cost scale-up.

Direct-compression strategy

A direct-compression formulation could use microcrystalline cellulose or lactose as the principal diluent, crospovidone or croscarmellose sodium as the disintegrant, colloidal silicon dioxide as the glidant, and magnesium stearate or sodium stearyl fumarate as the lubricant.

This approach can reduce granulation equipment requirements and manufacturing steps. It is attractive if molindone hydrochloride has adequate flow, compressibility, and content-uniformity performance at each strength.

Key development risks include:

• Poor powder flow at low drug loading.
• Segregation between molindone hydrochloride and excipient particles.
• Tablet capping or lamination.
• Over-lubrication and slower dissolution.
• Strength-dependent weight and blend-uniformity problems.

Wet-granulation strategy

Wet granulation may be preferable if the active ingredient has poor flow, weak compactability, or unacceptable segregation behavior. Povidone or starch can provide binding, while starch glycolate or crospovidone can restore rapid disintegration.

Wet granulation increases process complexity and cost. It may still be justified where it improves content uniformity, tablet hardness, dissolution reproducibility, or manufacturing yield.

Film-coating strategy

A film coat can improve appearance, reduce friability, support product identification, and improve swallowability. It also creates an opportunity to separate strengths by color or imprinting.

A coating is commercially useful when:

• The uncoated tablet has an unpleasant taste.
• The tablet is friable during packaging or transport.
• Patients have difficulty distinguishing strengths.
• A manufacturer wants a more modern presentation than a legacy tablet.

The coating should not materially delay immediate release unless the product is intentionally being developed as a modified-release dosage form.

What formulation patents could protect a new molindone product?

A conventional tablet made with standard excipients would have weak patent potential. The patent position improves only if the formulation provides a specific, non-obvious technical result.

Potential formulation patent targets

Orally disintegrating tablet

An orally disintegrating tablet could target patients with swallowing difficulty, psychiatric-care adherence challenges, or limited access to water. Patentable elements could include:

• A low-weight porous tablet structure.
• A specific superdisintegrant ratio.
• Taste masking for molindone hydrochloride.
• A moisture-controlled manufacturing process.
• A defined disintegration time and dissolution profile.

The principal risk is proving that the dosage form is sufficiently differentiated from known orally disintegrating antipsychotics.

Taste-masked tablet or multiparticulate

Taste masking could use polymer coating, lipid coating, complexation, or ion-exchange technology. Multiparticulates could be filled into capsules or compressed into tablets.

This opportunity is technically more defensible than a standard tablet, but it introduces dissolution, dose-uniformity, and scale-up risks.

Modified-release product

A once-daily or extended-release molindone product could create a differentiated product profile. Potential benefits include fewer daily doses, lower peak-to-trough variation, and improved adherence.

The development burden would be substantial. A sponsor would need to establish:

• A clinically justified pharmacokinetic profile.
• Dose proportionality or a suitable dose-conversion approach.
• Food-effect behavior.
• Alcohol-induced dose dumping performance.
• A clinically acceptable exposure range.
• New safety and efficacy support if the product differs materially from the historical immediate-release tablet.

A modified-release product could be pursued through a 505(b)(2) application rather than a conventional ANDA, depending on the reference and the degree of formulation change.

Co-processed excipient system

A co-processed excipient can improve flow, compactability, or low-dose uniformity. However, the patent value would depend on the specific composition and demonstrated performance, not merely on substituting one commercial excipient for another.

What FDA regulatory pathway applies to new molindone formulations?

A conventional immediate-release generic tablet would normally be developed through an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. A substantially changed dosage form may require a 505(b)(2) application.

Product concept	Likely pathway	Main evidence
Same-strength immediate-release tablet	ANDA	Pharmaceutical equivalence and bioequivalence
New tablet excipient system with same release profile	Usually ANDA	CMC data, comparative dissolution, bioequivalence
Orally disintegrating tablet	ANDA or 505(b)(2), depending on reference and changes	Bioequivalence, disintegration, stability, possibly clinical bridging
Extended-release tablet	505(b)(2) or suitable ANDA pathway	Pharmacokinetics, food effect, dose dumping, clinical bridging
Oral liquid	505(b)(2) or ANDA if an appropriate reference exists	Stability, preservative effectiveness, dosing accuracy, bioequivalence
Transdermal, injectable, or implantable product	505(b)(2)	New CMC and clinical development package

FDA guidance emphasizes that inactive ingredients cannot be treated as commercially interchangeable merely because they are commonly used. The sponsor must demonstrate that the full formulation meets quality, performance, and bioequivalence requirements. FDA’s Inactive Ingredient Database is useful for identifying precedent, but database presence does not eliminate formulation-specific review requirements.[1,2]

What generic entry risks exist for molindone hydrochloride?

Generic entry risk is high in legal terms but moderate in commercial terms.

Legal entry risk

A conventional ANDA applicant would face limited expected patent risk because:

• The original product is old.
• Standard tablet patents would be expired.
• No important current Orange Book patent estate is apparent.
• Paragraph IV litigation is unlikely unless a new sponsor obtains and lists a formulation or method-of-use patent.

A later entrant could still face non-patent barriers, including product discontinuation, reference-product availability, manufacturing-site qualification, and FDA inspection issues.

Commercial entry risk

The principal commercial risks are:

• Low prescription volume.
• Price compression after multiple generic entrants.
• Limited wholesaler interest.
• Inventory carrying costs across five strengths.
• Small batch sizes and inefficient packaging.
• Pharmacist substitution dynamics.
• Competition from risperidone, olanzapine, quetiapine, aripiprazole, haloperidol, and other antipsychotics.
• Limited physician familiarity with molindone.
• Potential difficulty obtaining favorable reimbursement.

A manufacturer should not assume that a patent-free product will support a high price. The value proposition is more likely to be supply reliability, low manufacturing cost, or a differentiated dosage form.

Which companies are challenging or supplying molindone hydrochloride?

Molindone hydrochloride has historically been associated with the original Moban product and later generic manufacturers. Generic availability has varied over time, and supplier status can change because of manufacturing decisions, shortages, acquisitions, and discontinuations.

The relevant competitive set should be evaluated through current FDA records, including:

• FDA Drugs@FDA.
• FDA Orange Book.
• FDA Drug Shortages database.
• DailyMed labeling.
• National Drug Code records.
• Wholesaler and institutional procurement data.

Public product records have identified generic supply under multiple manufacturer or labeler arrangements over time. Because the product is a small market, the competitive landscape can change rapidly when one manufacturer exits.

What commercial opportunities exist for molindone hydrochloride?

Low-cost generic supply

The most practical opportunity is a reliable generic tablet line with:

• One validated formulation across all strengths.
• High-yield compression.
• Simple packaging.
• Low minimum production quantities.
• Strong supply continuity.
• Contract manufacturing or regional production flexibility.

This strategy is suitable for a company with an existing oral-solid-dose platform and spare tablet capacity.

Institutional and shortage-resilience supply

Psychiatric hospitals, correctional systems, government purchasers, and long-term-care providers may value continuity more than formulation novelty. A supplier with dependable inventory and regulatory compliance can compete even in a low-volume category.

The product may also have procurement value where prescribers retain patients on legacy therapy and switching is clinically undesirable.

Orally disintegrating product

An orally disintegrating molindone product could target adherence and administration problems. Its commercial success would depend on evidence that it solves a real use-case, rather than simply duplicating an inexpensive tablet.

A practical formulation would need:

• Acceptable taste.
• Adequate mechanical strength.
• Rapid dispersion.
• Low moisture sensitivity.
• Packaging that protects against humidity.
• A clear strength-identification system.

Oral liquid

An oral liquid could support patients who cannot swallow tablets and institutions that require flexible dose measurement. The main formulation issues would be molindone hydrochloride solubility, pH control, chemical stability, preservative selection, container compatibility, and dosing accuracy.

A liquid product may face a smaller market than tablets but could command higher unit economics if it fills an actual supply gap.

Combination or adherence-focused products

A fixed-dose combination involving molindone would face substantial clinical and regulatory hurdles. A more realistic opportunity is an adherence-oriented product, such as an orally disintegrating tablet or a packaging system with strength-specific identification.

Global and regional licensing

Licensing opportunities are more likely to involve:

• Regional generic rights.
• Authorized generic supply.
• Contract manufacturing.
• Institutional tenders.
• Formulation technology licensing.
• Portfolio bundling with other psychiatric products.

A standalone royalty-bearing patent license would have limited value unless tied to a differentiated dosage form or manufacturing technology. The strongest commercial arrangement would likely combine product rights with manufacturing capacity and established distribution.

How strong is the patent estate for molindone hydrochloride?

The patent estate is weak for a standard tablet and potentially moderate for a genuinely differentiated delivery system.

Asset type	Patent strength	Commercial assessment
Conventional immediate-release tablet	Low	Difficult to defend against generic substitution
Novel excipient ratio	Low to moderate	Requires strong technical effect
Orally disintegrating tablet	Moderate	Defensible if taste, stability, and performance are distinctive
Extended-release product	Moderate to high	Higher development cost and clinical risk
Oral liquid	Moderate	Potential protection around stability and dosing system
Manufacturing process	Moderate	Useful if process materially lowers cost or improves purity
Packaging and adherence system	Low to moderate	Usually ancillary rather than a primary barrier

A formulation patent should claim measurable performance: dissolution, disintegration, stability, impurity control, bioavailability, or manufacturing yield. Claims limited to routine excipient substitutions are vulnerable to obviousness challenges.

What litigation and settlement issues affect molindone hydrochloride?

No major current Paragraph IV litigation or settlement framework is apparent for standard molindone hydrochloride tablets. The product’s age and limited market reduce the expected value of patent litigation.

Litigation risk could increase if a sponsor launches:

• An extended-release formulation.
• A branded orally disintegrating product.
• A liquid formulation with a new method of use.
• A product supported by a newly listed formulation patent.
• A manufacturing process with commercially important impurity-control claims.

For a standard ANDA, litigation budgeting should focus more on product liability, GMP enforcement, supply agreements, and substitution disputes than on Orange Book patent litigation.

How does molindone compare with competing antipsychotics?

Product	Market position	Formulation opportunity	Competitive pressure
Molindone hydrochloride	Legacy, niche typical antipsychotic	Supply continuity, ODT, liquid, low-cost generic	High from newer agents
Haloperidol	Established typical antipsychotic	Injectable and oral formulations	High
Risperidone	Broad generic use	ODT, liquid, long-acting injectable	Very high
Olanzapine	Broad use and multiple dosage forms	ODT and injectable	Very high
Quetiapine	High-volume atypical antipsychotic	Immediate- and extended-release	Very high
Aripiprazole	Broad use and long-acting injectable	ODT and depot products	Very high

Molindone’s principal advantage is the lack of a significant current patent barrier. Its principal disadvantage is limited clinical demand relative to newer antipsychotics.

What revenue exposure should investors expect?

Publicly available information does not support a reliable standalone revenue estimate for molindone hydrochloride. The product is best characterized as a low-revenue, niche generic opportunity rather than a major pharmaceutical asset.

Revenue potential depends on:

1. The number of active suppliers.
2. Current shortage or discontinuation conditions.
3. Institutional contract access.
4. Ability to supply all major strengths.
5. Manufacturing cost per batch.
6. Reimbursement and wholesaler deductions.
7. Whether the product is a standard generic or differentiated dosage form.

A standard tablet may generate modest revenue with limited development expense. A novel formulation may produce higher gross margin per unit but carries disproportionate bioequivalence, clinical, and market-adoption risk.

Key Takeaways

• Molindone hydrochloride is an old small-molecule antipsychotic with no meaningful current patent barrier apparent for standard immediate-release tablets.
• A conventional ANDA is the most economical route for a generic tablet.
• Excipients should prioritize low cost, blend uniformity, rapid disintegration, stability, and scalable tableting.
• Direct compression is attractive if flow and compressibility are adequate; wet granulation is a fallback for uniformity and mechanical-performance problems.
• Orally disintegrating tablets, oral liquids, and extended-release products offer the strongest formulation opportunities.
• A routine excipient substitution is unlikely to create strong patent protection.
• The commercial market is niche, and supply reliability may be more valuable than extensive product differentiation.
• Biosimilar competition does not apply.
• Paragraph IV litigation risk is expected to be low for a conventional generic.
• The principal business risks are low demand, generic price erosion, manufacturing economics, and competition from newer antipsychotics.

FAQs

Can molindone hydrochloride be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is a technically plausible 505(b)(2) or generic development opportunity, depending on the reference product and formulation changes. Taste masking, moisture control, mechanical strength, and rapid dissolution are the main development issues.

Is lactose suitable for molindone hydrochloride tablets?

Lactose can be suitable as a diluent if compatibility, moisture sensitivity, blend uniformity, and patient-specific excipient restrictions are acceptable. Microcrystalline cellulose or pregelatinized starch can provide alternatives for a lactose-free product.

Does molindone hydrochloride have biosimilar competition?

No. Molindone hydrochloride is a small-molecule drug. Competition would come from generic tablets or reformulated products, not biosimilars.

Could a molindone hydrochloride extended-release product obtain market exclusivity?

Potentially. A novel extended-release formulation could receive patent protection and regulatory exclusivity if it meets applicable requirements. The commercial case would require evidence that longer dosing intervals or improved pharmacokinetics justify development costs.

Is a new molindone hydrochloride tablet likely to face Paragraph IV litigation?

A conventional tablet is unlikely to face substantial Paragraph IV litigation because the original product is old and no significant current patent estate is apparent. Litigation risk would be higher only if a newer formulation patent were listed against the relevant reference product.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
3. U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book. https://www.fda.gov/drugsatfda
4. U.S. Food and Drug Administration. (n.d.). DailyMed: Molindone hydrochloride tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.